Article Sidebar
Views pdf: 0
CLINICAL EFFICACY AND SAFETY OF DAPAGLIFLOZIN IN HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION: REAL-WORLD EXPERIENCE AT CAN THO CENTRAL GENERAL HOSPITAL
Main Article Content
Abstract
Background: This study evaluated the efficacy and safety of dapagliflozin in patients with HFmrEF at Can Tho Central General Hospital. Objectives: To assess the clinical efficacy of dapagliflozin in HFmrEF and analyze its safety under real-world clinical practice. Methods: An uncontrolled clinical intervention was conducted in 99 patients. Data collected included clinical and paraclinical characteristics, length of stay, NYHA class changes, rehospitalization, and 30–90-day mortality. Results: Mean age was 70.43 ± 12.65 years; comorbidities included hypertension (98%), dyslipidemia (78.8%), and diabetes (35.4%). Mean LVEF was 43.93 ± 2.71%, with markedly elevated NT-proBNP. Dapagliflozin improved symptoms, enhanced NYHA class, reduced rehospitalization, with mean hospitalization 9.83 ± 3.31 days. Mortality was 3% and composite adverse events 19.2%, indicating a favorable safety profile. Conclusion: Dapagliflozin is an effective and safe therapeutic option, improving quality of life and prognosis in HFmrEF patients.
Article Details
Keywords
Dapagliflozin; Heart failure with mildly reduced ejection fraction (HFmrEF); Clinical effectiveness; Safety
References
2. Trang Nông Thị Huyền Trang, Nguyễn Trọng Hiếu (2024), "Kết quả điều trị bằng phác đồ có phối hợp thuốc dapagliflozin ở bệnh nhân suy tim có phân suất tống máu thất trái giảm tại Bệnh viện Trung ương Thái Nguyên", Tạp chí Y học Việt Nam, 545(2), 86-90.
3. Phạm Nguyễn Vinh, Phạm Mạnh Hùng (2022), "Hội tim mạch học Quốc gia Việt Nam", Khuyến cáo của Hội Tim mạch quốc gia về chẩn đoán và điều trị suy tim cấp và suy tim mạn (2022).
4. Solomon S. D., McMurray J. J. V., Claggett B., de Boer R. A., DeMets D., Hernandez A. F., et al. (2022), "Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction", New England Journal of Medicine, 387(12), 1089–1098.
5. Siqueira S. R. O., Solomon S. D., McMurray J. J. V., Claggett B., de Boer R. A., Kosiborod M., et al. (2025), "Achieved ejection fraction and effects of dapagliflozin in heart failure with improved ejection fraction", Journal of the American College of Cardiology: Heart Failure. Advance online publication, 13(10), 1-13.
6. Nguyen S. V., Do T. M., Tran T. X., Nguyen T. T., & Pham D. T. M. (2022), "Prevalence, treatment, and 1-year outcomes of heart failure with mid-range ejection fraction", Biomedical Research and Therapy, 9(8), 5209-5215.
7. Toan N. H., Thuan N. T., Cuong V. T., Ngan L. D., Diep D. T. N., & Son T. K. (2024), "The rate and outcomes of reducing re-hospitalizations with a treatment regimen including dapagliflozin in heart failure with reduced ejection fraction without diabetes patients", Can Tho Journal of Medicine and Pharmacy, 10(7), 1-7.
8. Van Nguyen T., Nguyen H.T.K., Wong W.J. et al. (2024), "The prescription of beta-blockers in older patients with heart failure with reduced ejection fraction: an observational study in Vietnam", Scientific Reports, 14, 12923.
9. Chatur S., Kondo T., Claggett B. L., Vaduganathan M., Jhund P. S., de Boer R. A., et al. (2023), "Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HF", European Journal of Heart Failure, 25(8), 1364-1371.
10. Huynh TLT, Pham PT, Tran HD, Tran ND, Tran DV, Tran BLT, et al. (2024), "Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure", PeerJ, 12, e18595.